IBO — IMPACT BIOMEDICAL INC.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1834105 ·
Last close
$6.17
Market Cap
$53.31M
52W High
$10.51
52W Low
$2.43
ADV30
15,916
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 21,000 | 15,000 | -648,000 | -645,000 | 16,427,000 | 21,000 | 3,061,000 |
| Jun 2026 | 3,000 | 2,000 | -702,000 | -699,000 | 16,745,000 | 10,000 | 2,733,000 |
| Mar 2026 | 7,000 | — | -2,289,000 | -2,287,000 | 17,086,000 | 20,000 | 2,375,000 |
| Dec 2025 | 7,000 | -415,000 | -1,158,000 | 5,245,000 | 17,405,000 | 3,000 | 1,850,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$116,000
Investing CF
$2,000
Financing CF
$373,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.98
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-53,139,000
Inventory
$56,000
Receivables
$14,000
ST Investments
—
EBIT TTM
$-973,000
Pretax Income TTM
$-973,000
Interest Exp TTM
$0
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,000
EBITDA
$-4,225,000
Free Cash Flow
$436,500
Enterprise Value
$47,635,600
Total Cash
$21,000
Total Debt
$0
Shares Out
8,640,000
Trailing EPS
$11.11
Book Value
$1.52
ROE
71.2%
ROA
-17.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,000 | -4,270,000 | -11,838,000 | 17,405,000 | 1,850,000 | 12,609,000 | -1,890,000 |
| Dec 2024 | 0 | -3,397,000 | -24,708,000 | 20,290,000 | 13,053,000 | 4,259,000 | -2,854,000 |
| Dec 2023 | 0 | -4,028,000 | -4,336,000 | 44,633,000 | 16,371,000 | 25,222,000 | -2,851,000 |
| Dec 2022 | 50,000 | -3,404,000 | -7,051,000 | 46,497,000 | 13,828,000 | 29,558,000 | -2,242,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$35,000
NetIncome TTM
$789,000
OpCashFlow TTM
—
Assets (Latest)
$16,745,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | $53.26M | $7.54 | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $53.70M | $0.28 | — |
| IBIO | iBio, Inc. | $52.71M | $0.75 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $53.94M | $3.14 | — |
| GANX | Gain Therapeutics, Inc. | $52.54M | $1.18 | — |
News headlines (Yahoo Finance, 1h cache)
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
2026-11-18 13:05 · Yahoo
Zoar Limited Completes Business Combination with Impact Biomedical Inc.
2026-11-18 13:00 · Yahoo
DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination
2026-11-03 04:33 · Yahoo
Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination
2026-11-03 04:25 · Yahoo
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
2026-09-16 13:25 · Yahoo
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
2026-09-16 13:20 · Yahoo
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
2026-09-15 01:26 · Yahoo
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
2026-09-11 20:05 · Yahoo
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
2026-04-03 17:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.